Brian Harry
Concepts (187)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Free Tissue Flaps | 3 | 2016 | 29 | 1.170 |
Why?
| Reconstructive Surgical Procedures | 2 | 2013 | 259 | 0.810 |
Why?
| Fascia Lata | 1 | 2013 | 6 | 0.540 |
Why?
| Abdominal Muscles | 1 | 2013 | 12 | 0.540 |
Why?
| Fasciitis, Necrotizing | 1 | 2013 | 10 | 0.540 |
Why?
| Abdominal Wall | 1 | 2013 | 23 | 0.530 |
Why?
| Back | 1 | 2013 | 9 | 0.530 |
Why?
| Myocutaneous Flap | 1 | 2013 | 5 | 0.530 |
Why?
| Arteriovenous Shunt, Surgical | 1 | 2013 | 22 | 0.510 |
Why?
| Cleft Lip | 1 | 2012 | 37 | 0.490 |
Why?
| Meningioma | 1 | 2013 | 68 | 0.490 |
Why?
| Janus Kinase 2 | 1 | 2012 | 35 | 0.490 |
Why?
| Cleft Palate | 1 | 2012 | 49 | 0.490 |
Why?
| Meningeal Neoplasms | 1 | 2013 | 76 | 0.480 |
Why?
| Apolipoproteins E | 3 | 2008 | 103 | 0.450 |
Why?
| Caenorhabditis elegans Proteins | 4 | 2016 | 235 | 0.450 |
Why?
| Hematologic Neoplasms | 1 | 2012 | 121 | 0.440 |
Why?
| DNA Fragmentation | 1 | 2010 | 62 | 0.440 |
Why?
| Ribonuclease III | 1 | 2010 | 34 | 0.440 |
Why?
| Caenorhabditis elegans | 4 | 2016 | 369 | 0.410 |
Why?
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2008 | 55 | 0.370 |
Why?
| Atherosclerosis | 2 | 2008 | 301 | 0.370 |
Why?
| Apoptosis | 3 | 2016 | 2662 | 0.330 |
Why?
| Endothelial Cells | 2 | 2008 | 641 | 0.300 |
Why?
| Protein Kinase Inhibitors | 1 | 2012 | 853 | 0.300 |
Why?
| Heparin | 2 | 2016 | 210 | 0.260 |
Why?
| Vaccination | 2 | 2021 | 932 | 0.260 |
Why?
| Intracellular Space | 2 | 2012 | 81 | 0.250 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2012 | 217 | 0.230 |
Why?
| Immunity, Humoral | 1 | 2021 | 93 | 0.220 |
Why?
| Trans-Activators | 2 | 2012 | 428 | 0.200 |
Why?
| Neoplasms | 1 | 2012 | 2009 | 0.190 |
Why?
| Antibodies, Viral | 1 | 2021 | 512 | 0.180 |
Why?
| Proteome | 1 | 2021 | 335 | 0.180 |
Why?
| Arachidonate 12-Lipoxygenase | 2 | 2009 | 16 | 0.170 |
Why?
| Arachidonate 15-Lipoxygenase | 2 | 2009 | 19 | 0.170 |
Why?
| Nuclear Pore Complex Proteins | 1 | 2016 | 28 | 0.170 |
Why?
| Macrophages | 3 | 2008 | 1338 | 0.160 |
Why?
| Tissue and Organ Harvesting | 1 | 2016 | 63 | 0.160 |
Why?
| Fertilization | 1 | 2016 | 53 | 0.160 |
Why?
| Endodeoxyribonucleases | 1 | 2016 | 64 | 0.160 |
Why?
| Chemoprevention | 1 | 2016 | 92 | 0.160 |
Why?
| Calcium | 2 | 2012 | 1215 | 0.160 |
Why?
| Proteomics | 1 | 2021 | 759 | 0.150 |
Why?
| Acute Lung Injury | 2 | 2009 | 325 | 0.150 |
Why?
| Caspases | 1 | 2016 | 293 | 0.150 |
Why?
| Proteins | 1 | 2021 | 992 | 0.150 |
Why?
| DNA, Mitochondrial | 1 | 2016 | 200 | 0.140 |
Why?
| Venous Thrombosis | 1 | 2016 | 137 | 0.140 |
Why?
| Mitochondrial Proteins | 1 | 2016 | 227 | 0.140 |
Why?
| Lower Extremity | 1 | 2016 | 246 | 0.130 |
Why?
| Administration, Intravenous | 1 | 2013 | 142 | 0.130 |
Why?
| RNA, Small Interfering | 2 | 2021 | 605 | 0.130 |
Why?
| Anticoagulants | 2 | 2016 | 532 | 0.120 |
Why?
| Mitochondria | 2 | 2016 | 808 | 0.120 |
Why?
| Animals | 12 | 2016 | 35194 | 0.120 |
Why?
| Capillary Permeability | 2 | 2009 | 166 | 0.120 |
Why?
| Femoral Artery | 1 | 2013 | 163 | 0.120 |
Why?
| Blood Flow Velocity | 1 | 2013 | 378 | 0.120 |
Why?
| Postoperative Period | 1 | 2012 | 287 | 0.120 |
Why?
| Hepatocytes | 1 | 2012 | 203 | 0.110 |
Why?
| Humans | 14 | 2021 | 112255 | 0.110 |
Why?
| Mice, Knockout | 5 | 2009 | 2888 | 0.110 |
Why?
| In Situ Nick-End Labeling | 1 | 2010 | 138 | 0.110 |
Why?
| Interleukin-4 | 2 | 2008 | 231 | 0.100 |
Why?
| Lipoxygenase Inhibitors | 1 | 2009 | 40 | 0.100 |
Why?
| Virus Replication | 1 | 2012 | 432 | 0.100 |
Why?
| Duffy Blood-Group System | 1 | 2009 | 8 | 0.100 |
Why?
| Bone Marrow Transplantation | 2 | 2008 | 291 | 0.100 |
Why?
| Multienzyme Complexes | 1 | 2009 | 74 | 0.100 |
Why?
| Chemokines, CXC | 1 | 2009 | 68 | 0.100 |
Why?
| Vascular Cell Adhesion Molecule-1 | 1 | 2008 | 52 | 0.090 |
Why?
| Aorta, Abdominal | 1 | 2008 | 38 | 0.090 |
Why?
| Granulomatous Disease, Chronic | 1 | 2008 | 64 | 0.090 |
Why?
| Phosphatidylserines | 1 | 2008 | 94 | 0.090 |
Why?
| Mice, Inbred C57BL | 5 | 2009 | 5232 | 0.090 |
Why?
| Receptors, CXCR | 1 | 2007 | 5 | 0.090 |
Why?
| Cells, Cultured | 4 | 2009 | 4413 | 0.090 |
Why?
| Bone Marrow Cells | 1 | 2008 | 330 | 0.080 |
Why?
| Receptors, Cell Surface | 1 | 2009 | 401 | 0.080 |
Why?
| Phagocytosis | 1 | 2008 | 386 | 0.080 |
Why?
| Regional Blood Flow | 1 | 2008 | 443 | 0.080 |
Why?
| Stress, Mechanical | 1 | 2008 | 472 | 0.080 |
Why?
| RNA Interference | 1 | 2008 | 514 | 0.080 |
Why?
| Aorta, Thoracic | 1 | 2008 | 241 | 0.080 |
Why?
| Dietary Fats | 1 | 2008 | 354 | 0.080 |
Why?
| Postoperative Complications | 1 | 2016 | 2095 | 0.070 |
Why?
| Mice | 7 | 2012 | 15510 | 0.070 |
Why?
| Foam Cells | 1 | 2004 | 17 | 0.070 |
Why?
| Dinoprost | 1 | 2004 | 34 | 0.070 |
Why?
| Hyperlipoproteinemia Type II | 1 | 2004 | 26 | 0.070 |
Why?
| Arteriosclerosis | 1 | 2004 | 111 | 0.070 |
Why?
| Middle Aged | 3 | 2016 | 28678 | 0.070 |
Why?
| NF-kappa B | 1 | 2008 | 715 | 0.070 |
Why?
| Macrophages, Peritoneal | 1 | 2004 | 113 | 0.070 |
Why?
| Disease Models, Animal | 3 | 2009 | 3892 | 0.070 |
Why?
| Erythrocytes | 1 | 2009 | 602 | 0.070 |
Why?
| Interferon-gamma | 1 | 2007 | 804 | 0.070 |
Why?
| Viral Regulatory and Accessory Proteins | 2 | 2012 | 23 | 0.060 |
Why?
| Cell Differentiation | 2 | 2008 | 1824 | 0.060 |
Why?
| Myocytes, Smooth Muscle | 1 | 2004 | 244 | 0.060 |
Why?
| Amino Acid Motifs | 2 | 2012 | 214 | 0.060 |
Why?
| Geminin | 1 | 2021 | 2 | 0.060 |
Why?
| Fucose | 1 | 2021 | 6 | 0.060 |
Why?
| Cycloheximide | 1 | 2021 | 72 | 0.060 |
Why?
| Cytosol | 2 | 2012 | 250 | 0.060 |
Why?
| HCT116 Cells | 1 | 2021 | 76 | 0.060 |
Why?
| Alanine | 1 | 2021 | 103 | 0.060 |
Why?
| Quality Control | 1 | 2021 | 176 | 0.060 |
Why?
| Vaccines, Synthetic | 1 | 2021 | 90 | 0.060 |
Why?
| Principal Component Analysis | 1 | 2021 | 183 | 0.060 |
Why?
| Disease Progression | 1 | 2008 | 2474 | 0.050 |
Why?
| Immunity | 1 | 2021 | 124 | 0.050 |
Why?
| Telomere | 1 | 2021 | 200 | 0.050 |
Why?
| Treatment Outcome | 1 | 2013 | 8944 | 0.050 |
Why?
| Protein Biosynthesis | 1 | 2021 | 406 | 0.050 |
Why?
| Infant | 1 | 2012 | 8024 | 0.050 |
Why?
| T-Lymphocytes | 1 | 2007 | 1843 | 0.050 |
Why?
| HEK293 Cells | 1 | 2021 | 662 | 0.050 |
Why?
| Mice, Inbred BALB C | 2 | 2012 | 1326 | 0.040 |
Why?
| Male | 6 | 2016 | 60721 | 0.040 |
Why?
| Ultrasonography, Doppler, Duplex | 1 | 2016 | 28 | 0.040 |
Why?
| Retrospective Studies | 1 | 2012 | 11118 | 0.040 |
Why?
| Thigh | 1 | 2016 | 53 | 0.040 |
Why?
| Germ Cells | 1 | 2016 | 51 | 0.040 |
Why?
| Mitochondrial Membranes | 1 | 2016 | 36 | 0.040 |
Why?
| Protein Binding | 2 | 2012 | 2112 | 0.040 |
Why?
| Proteasome Endopeptidase Complex | 1 | 2016 | 142 | 0.040 |
Why?
| Protein Interaction Domains and Motifs | 1 | 2016 | 144 | 0.040 |
Why?
| Peptides | 1 | 2021 | 882 | 0.040 |
Why?
| Spermatozoa | 1 | 2016 | 105 | 0.040 |
Why?
| Embryo, Nonmammalian | 1 | 2016 | 206 | 0.040 |
Why?
| Lipopolysaccharides | 2 | 2009 | 956 | 0.040 |
Why?
| Cell Line | 1 | 2021 | 3013 | 0.040 |
Why?
| Mutation, Missense | 1 | 2016 | 324 | 0.030 |
Why?
| Enzyme Activation | 1 | 2016 | 961 | 0.030 |
Why?
| Cell Line, Tumor | 1 | 2021 | 2919 | 0.030 |
Why?
| Female | 4 | 2016 | 62627 | 0.030 |
Why?
| Genes, Suppressor | 1 | 2012 | 6 | 0.030 |
Why?
| Hepatitis B virus | 1 | 2012 | 20 | 0.030 |
Why?
| bcl-X Protein | 1 | 2012 | 45 | 0.030 |
Why?
| Hep G2 Cells | 1 | 2012 | 77 | 0.030 |
Why?
| Permeability | 1 | 2012 | 161 | 0.030 |
Why?
| Autophagy | 1 | 2016 | 307 | 0.030 |
Why?
| Necrosis | 1 | 2012 | 232 | 0.030 |
Why?
| Cell Death | 1 | 2012 | 348 | 0.030 |
Why?
| 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid | 1 | 2009 | 4 | 0.030 |
Why?
| Caffeic Acids | 1 | 2009 | 3 | 0.030 |
Why?
| Endothelium, Vascular | 2 | 2009 | 971 | 0.030 |
Why?
| Chemokine CXCL2 | 1 | 2009 | 55 | 0.030 |
Why?
| Incidence | 1 | 2016 | 2453 | 0.020 |
Why?
| Chimera | 1 | 2009 | 60 | 0.020 |
Why?
| Chemokine CXCL1 | 1 | 2009 | 73 | 0.020 |
Why?
| NADPH Oxidase 2 | 1 | 2008 | 48 | 0.020 |
Why?
| Microcirculation | 1 | 2009 | 165 | 0.020 |
Why?
| Jurkat Cells | 1 | 2008 | 145 | 0.020 |
Why?
| Receptors, CXCR6 | 1 | 2007 | 1 | 0.020 |
Why?
| NADPH Oxidases | 1 | 2008 | 161 | 0.020 |
Why?
| Amino Acid Sequence | 1 | 2012 | 2228 | 0.020 |
Why?
| Administration, Inhalation | 1 | 2009 | 645 | 0.020 |
Why?
| Molecular Sequence Data | 1 | 2012 | 3120 | 0.020 |
Why?
| Follow-Up Studies | 1 | 2016 | 4888 | 0.020 |
Why?
| Aortic Diseases | 1 | 2007 | 99 | 0.020 |
Why?
| Bronchoalveolar Lavage Fluid | 1 | 2009 | 655 | 0.020 |
Why?
| Membrane Glycoproteins | 1 | 2008 | 507 | 0.020 |
Why?
| Colorado | 1 | 2016 | 4552 | 0.020 |
Why?
| Protein Transport | 1 | 2007 | 455 | 0.020 |
Why?
| Inflammation Mediators | 1 | 2009 | 555 | 0.020 |
Why?
| Survival Analysis | 1 | 2009 | 1414 | 0.020 |
Why?
| Green Fluorescent Proteins | 1 | 2007 | 426 | 0.020 |
Why?
| Radiation Chimera | 1 | 2004 | 39 | 0.020 |
Why?
| Prospective Studies | 1 | 2016 | 6168 | 0.020 |
Why?
| Autocrine Communication | 1 | 2004 | 42 | 0.020 |
Why?
| Time Factors | 1 | 2016 | 7054 | 0.020 |
Why?
| Cell Movement | 1 | 2009 | 930 | 0.020 |
Why?
| Lipoproteins, LDL | 1 | 2004 | 149 | 0.020 |
Why?
| Cell Adhesion | 1 | 2004 | 474 | 0.020 |
Why?
| Neutrophils | 1 | 2009 | 1322 | 0.020 |
Why?
| Triglycerides | 1 | 2004 | 542 | 0.010 |
Why?
| Mice, Transgenic | 1 | 2007 | 2159 | 0.010 |
Why?
| Mutation | 1 | 2012 | 3421 | 0.010 |
Why?
| Muscle, Smooth, Vascular | 1 | 2004 | 482 | 0.010 |
Why?
| Signal Transduction | 1 | 2012 | 4914 | 0.010 |
Why?
| Aged | 1 | 2016 | 20026 | 0.010 |
Why?
| RNA, Messenger | 1 | 2004 | 2847 | 0.010 |
Why?
| Lung | 1 | 2009 | 3587 | 0.010 |
Why?
| Adult | 1 | 2016 | 31793 | 0.010 |
Why?
|
|
Harry's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|